Lv6
2425 积分 2021-03-06 加入
MDX2003, a novel tetraspecific T cell engager-expander targeting CD19xCD20xCD3xCD28, demonstrates potent preclinical activity against B cell malignancies
7小时前
求助中
16P MDX2003, a first-in-class CD19xCD20xCD3xCD28 tetraspecific T cell engager (TCE) with potent activity against B cell malignancies and promise in autoimmunity
10小时前
待确认
IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma
2天前
已完结
Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
6天前
已完结
The molecular blueprint of targeted radionuclide therapy
15天前
已完结
Navigating the safety profile of Actinium-225 targeted alpha therapy: a comprehensive review
16天前
已完结
Lung metastases
24天前
已完结
Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells
24天前
已完结
Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides
29天前
已完结
Clinical perspective on targeted alpha therapy using 225Ac
30天前
已完结
皖公网安备34019202002308
